Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension

doi:10.1016/j.jep.2014.09.049

科研成果详情

题名	Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension
作者	Lan, Jiarong 1,2; Zhao, Yanyun 1; Dong, Feixia 1,2,3,4,7; Yan, Ziyou 2; Zheng, Wenjie3,4; Fan, Jinping 5; Sun, Guoli 6
发表期刊	JOURNAL OF ETHNOPHARMACOLOGY 影响因子和分区
语种	英语
原始文献类型	Review
关键词	Meta-analysis Berberine Type 2 diabetes mellitus Hyperlipemia Hypertension
摘要	Ethnopharmacological relevance: Berberine, extracted from Coptis Root and Phellodendron Chinese, has been frequently used for the adjuvant treatment of type 2 diabetes mellitus, hyperlipidemia, and hypertension in China. Safety and efficacy studies in terms of evidence-based medical practice have become more prevalent in application to Chinese Herbal Medicine. It is necessary to assess the efficacy and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipidemia and hypertension by conducting a systematic review and meta-analysis of available clinical data. Materials and methods: We searched the English databases PubMed, ScienceDirect, Cochrane library, EMbase, etc., and Chinese databases including China biomedical literature database (CBM), Chinese Technology journal Full-text Database, Chinese journal full text database (CNKI), and Wanfang digital periodical full text database. Relevant studies were selected based on the inclusion and exclusion criteria. Meta-analysis was performed with RevMan5.0 software after data extraction and the quality of studies assessment. Results: Twenty-seven randomized controlled clinical trials were included with 2569 patients. There are seven subgroups in our meta-analysis: berberine versus placebo or berberine with intensive lifestyle intervention versus intensive lifestyle intervention alone; berberine combined with oral hypoglycemic versus hypoglycemic alone; berberine versus oral hypoglycemic; berberine combined with oral lipid lowering drugs versus lipid lowering drugs alone; berberine versus oral lipid lowering drugs; berberine combined with oral hypotensor versus hypotensive medications; berberine versus oral hypotensive medications. In the treatment of type 2 diabetes mellitus, we found that berberine with lifestyle intervention tended to lower the level of FPG, PPG and HbA(1c) than lifestyle intervention alone or placebo; the same as berberine combined with oral hypoglycaemics to the same hypoglycaemics; but there was no statistical significance between berberine and oral hypoglycaemics. As for the treatment of hyperlipidemia, berberine with lifestyle intervention was better than lifestyle intervention, berberine with oral lipid lowering drugs was better than lipid lowering drugs alone in reducing the level of TC and LDL-C, and raising the level of HDL-C. In the comparative study between berberine and oral lipid lowering drugs, there was no statistical significance in reducing the level of TC and LDL-C, but berberine shows better effect in lowering the level of TG and raising the level of HDL-C. In the treatment of hypertension, berberine with lifestyle intervention tended to lower the level of blood pressure more than the lifestyle intervention alone or placebo did; The same occurred when berberine combined with oral hypotensor was compared to the same hypotensor. Notably, no serious adverse reaction was reported in the 27 experiments. Conclusion: This study indicates that berberine has comparable therapeutic effect on type 2 DM, hyperlipidemia and hypertension with no serious side effect. Considering the relatively low cost compared with other first-line medicine and treatment, berberine might be a good alternative for low socioeconomic status patients to treat type 2 DM, hyperlipidemia, hypertension over long time period. Due to overall limited quality of the included studies, the therapeutic benefit of berberine can be substantiated to a limited degree. Better methodological quality, large controlled trials using standardized preparation are expected to further quantify the therapeutic effect of berberine. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
资助项目	Zhejiang Provincial Natural Science Foundation of China from the Natural Science Foundation of Zhejiang Province 151 [LY14H270001]; Wenzhou Municipal 551 Talented Grant; Grant of high level talents in Wenzhou and Wenzhou Municipal Health Bureau of Grant [2010A012]; Grant of Wenzhou Traditional Chinese Medicine Laboratory Center; Zhejiang Province Chinese Medicine Scientific Research Fund [2013ZB121]; Wenzhou Science 82 Technology Bureau of Grant [Y20100222]
出版者	ELSEVIER IRELAND LTD
出版地	CLARE
ISSN	0378-8741
EISSN	1872-7573
卷号	161 页码:69-81
DOI	10.1016/j.jep.2014.09.049
WOS类目	Plant Sciences ; Chemistry, Medicinal ; Integrative & Complementary Medicine ; Pharmacology & Pharmacy
WOS研究方向	Plant Sciences ; Pharmacology & Pharmacy ; Integrative & Complementary Medicine
WOS记录号	WOS:000349731100009
收录类别	SCIE ; PUBMED ; SCOPUS
发表日期	2015-02-23
URL	查看原文
Pubmed记录号	25498346
Scopus记录号	2-s2.0-84919665946
ESI高被引论文	2020-01 ; 2020-03 ; 2020-05 ; 2020-09 ; 2020-11 ; 2021-01 ; 2021-03 ; 2021-05 ; 2021-07 ; 2021-09 ; 2021-11 ; 2022-01 ; 2022-03 ; 2022-05 ; 2022-07 ; 2022-09 ; 2022-11 ; 2023-01 ; 2023-03 ; 2023-05 ; 2023-07 ; 2023-09 ; 2023-11 ; 2024-01 ; 2024-03 ; 2024-05
引用统计	被引频次：253[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/11216
专题	第二临床医学院、附属第二医院、育英儿童医院
通讯作者	Dong, Feixia
作者单位	1.Affiliated Zhejiang Univ Tradit Chinese Med, Wenzhou Hosp Tradit Chinese Med, Wenzhou 32500, Peoples R China; 2.Jiangxi Univ Tradit Chinese Med, Nanchang 330006, Peoples R China; 3.Wenzhou Med Univ, Affiliated Hosp 2, Wenzhou 325035, Peoples R China; 4.Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325035, Peoples R China; 5.Ctr Primary Care & Integrat Med PLLC, Houston, TX 77090 USA; 6.Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; 7.Zhejiang Univ Tradit Chinese Med, Hangzhou 310053, Zhejiang, Peoples R China
通讯作者单位	第二临床医学院，附属第二医院、育英儿童医院; 附属第二医院
推荐引用方式 GB/T 7714	Lan, Jiarong,Zhao, Yanyun,Dong, Feixia,et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension[J]. JOURNAL OF ETHNOPHARMACOLOGY,2015,161:69-81.
APA	Lan, Jiarong., Zhao, Yanyun., Dong, Feixia., Yan, Ziyou., Zheng, Wenjie., ... & Sun, Guoli. (2015). Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. JOURNAL OF ETHNOPHARMACOLOGY, 161, 69-81.
MLA	Lan, Jiarong,et al."Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension".JOURNAL OF ETHNOPHARMACOLOGY 161(2015):69-81.